Asked by: Simon Burns (Conservative - Chelmsford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, how many outpatient and inpatient appointments were (a) emergency and (b) elective with a (i) primary and (ii) secondary diagnosis of HIV in (A) England and (B) each clincial commissioning group area in each of the last 12 months; and what the average waiting time was for each such appointment.
Answered by Jane Ellison
The available information is set out in the attachments from Public Health England and the Health and Social Care Information Centre.
Asked by: Simon Burns (Conservative - Chelmsford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, when his Department next plans to publish data derived from the HIV and AIDS reporting system (HARS); what data from HARS will be made available publicly and at what frequency; and if he will make a statement.
Answered by Jane Ellison
The human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) Reporting System (HARS) is a new, integrated reporting system for information on adults living with diagnosed HIV infection in England. It will be designated as an Official Statistic. A full data set from HARS is not yet available. HARS data relating to 2015 will be available in the summer of 2016 and published on an annual basis thereafter to inform and evaluate the public health response to HIV. The publication of the HARS data HARS data to inform commissioning will be made available to commissioners on a quarterly basis.
Asked by: Simon Burns (Conservative - Chelmsford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, how much the NHS spent on (a) all drugs, (b) cancer drugs and (c) drugs funded through the Cancer Drug Fund in each of the last five years for which figures are available.
Answered by George Freeman
Figures provided for Primary Care for total drug spend are the total of net ingredient cost (NIC) and for Secondary Care the cost of the medicines at NHS list price.
Cost of drugs in primary and secondary care, England: 2009-10 to 2013-14 | |||||
Total drugs |
| Cost (£ million) | |||
| Primary Care1 | Secondary Care2 | Total | ||
2009-10 | 8,621.4 | 3,890.8 | 12,512.2 | ||
2010-11 | 8,881.1 | 4,173.9 | 13,055.0 | ||
2011-12 | 8,778.0 | 4,497.6 | 13,275.5 | ||
2012-13 | 8,439.0 | 5,020.8 | 13,459.8 | ||
2013-14 | 8,703.2 | 5,780.6 | 14,483.8 | ||
Sources: Prescription Cost Analysis (PCA), IMS HEALTH: Hospital Pharmacy Audit | |||||
Cost of cancer drugs3 in primary and secondary care, England: 2009-10 to 2013-14 | |||||
Total drugs |
| Cost (£ million) | |||
| Primary Care1,4 | Secondary Care2 | Total | ||
2009-10 | 230.2 | 748.1 | 978.3 | ||
2010-11 | 228.2 | 846.1 | 1,074.3 | ||
2011-12 | 190.0 | 964.1 | 1,154.1 | ||
2012-13 | 142.0 | 1,119.6 | 1,261.6 | ||
2013-14 | 143.0 | 1,350.2 | 1,493.2 | ||
Sources: PCA, IMS HEALTH: Hospital Pharmacy Audit | |||||
Spend through the Cancer Drugs Fund between October 2010 and March 2014 |
| ||||
Year | Spend (£000’s) |
| |||
2010-11 (Q3 and Q4) | 38,254 |
| |||
2011-12 | 108,327 |
| |||
2012-13 | 175,334 |
| |||
2013-14 | 230,539 |
| |||
Source: Prior to April 2013, information supplied to the Department by strategic health authorities. From April 2013, information supplied by NHS England.
Notes:
1 Primary Care NIC is the basic cost of the drug, which does not take account of discounts, dispensing costs, fees or prescription charges income.
2 Secondary care cost is the cost of the medicines at NHS list price which may not reflect the price the hospital paid.
3 Cancer drugs are defined by British National Formulary Sections 8.1 Cytotoxic drugs,
8.2.3 Anti-lymphocyte monoclonal antibodies (but also used in other indications), 8.2.4 Other immunomodulating drugs (Interferon-Alfa, Aldesleukin, Bacillus Calmette-Guerin (B.C.G.), Lenalidomide, Pomalidomide, Thalidomide and Mifamurtide only), and 8.3 Sex hormones and hormone antagonists in malignant disease.
4 The main reason for the reduction in cancer drugs in Primary Care is the introduction of lower cost generic formulations.
Asked by: Simon Burns (Conservative - Chelmsford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what medicines the National Institute for Health and Care Excellence (NICE) (a) has evaluated and (b) intends to evaluate using the highly specialised technologies process; and what medicines his Department is planning to refer to NICE for assessment through that process.
Answered by George Freeman
The National Institute for Health and Care Excellence (NICE) has been asked to evaluate the following treatments under its highly specialised technologies (HST) programme:
Assessment title | Anticipated publication date |
Atypical haemolytic uraemic syndrome - eculizumab | January 2015 |
Gaucher disease (type 1) - eliglustat | August 2015 |
Mucopolysaccharidosis (type IVA) - elosulfase alfa | October 2015 |
Paediatric-onset hypophosphatasia - asfotase alfa | October 2015 |
NICE has not yet issued any final guidance through this programme.
A number of other medicines are being considered for referral to NICE’s HST programme through the established topic selection arrangements. Information on these is currently commercially confidential and cannot be released at this stage.
Asked by: Simon Burns (Conservative - Chelmsford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what prescriptions were dispensed in the community for the (a) prevention and (b) treatment of cardiovascular disease in (i) England and (ii) each local commissioning organisation in each of the last 10 years.
Answered by George Freeman
Dispensed prescription data does not distinguish between medicines dispensed for prevention and treatment. Available data for the total number of prescription items written in England for cardiovascular medicines, as defined by British National Formulary Section Chapter 2, Cardivascular system, and dispensed in the United Kingdom, is attached.
The England level data has been extracted from the Prescription Cost Analysis (PCA) database, administered by the Health and Social Care Information Centre (HSCIC), and is provided for the 10 year period 2004-05 to 2013-14. As PCA data are not available for local commissioning organisations, these data have been extracted from the HSCIC’s iView online database, which is based on ePACT data. Information has been provided by primary care trust for the period 2008-09 to 2012-13. For 2013-14, data are provided at clinical commissioning group level, reflecting the National Health Service organisational changes in April 2013. Information prior to 2008-09 is not available.
Asked by: Simon Burns (Conservative - Chelmsford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what proportion of patients have been recorded through the Quality and Outcomes Framework as having total cholesterol at 5mmol/l or less in (a) England and (b) each local commissioning organisation in each of the last five years.
Answered by Jane Ellison
Information on the number of patients on the four Quality and Outcomes Framework registers containing a measure of cholesterol is set out in the attached tables for England and for each clinical commissioning group/primary care trust in England.
Asked by: Simon Burns (Conservative - Chelmsford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what prescriptions have been dispensed in the community for the (a) prevention and (b) treatment of high cholesterol in (i) England and (ii) each local commissioning organisation in each of the last 10 years.
Answered by George Freeman
Dispensed prescription data does not distinguish between medicines dispensed for prevention and treatment. Available data for the total number of prescription items written in England for cardiovascular medicines, as defined by British National Formulary Section 2.12 Lipid-regulating drugs, and dispensed in the United Kingdom, is attached.
The England level data has been extracted from the Prescription Cost Analysis (PCA) database, administered by the Health and Social Care Information Centre (HSCIC), and is provided for the 10 year period 2004-05 to 2013-14. As PCA data are not available for local commissioning organisations, these data have been extracted from the HSCIC’s iView online database, which is based on ePACT data. Information has been provided by primary care trust for the period 2008-09 to 2012-13. For 2013-14, data are provided at clinical commissioning group level, reflecting the National Health Service organisational changes in April 2013. Information prior to 2008-09 is not available.
Asked by: Simon Burns (Conservative - Chelmsford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, what hospital prescriptions have been used in the (a) prevention and (b) treatment of high cholesterol in (i) England and (ii) each local commissioning organisation in each of the last 10 years.
Answered by George Freeman
The available data, hospital dispensing information (HPAI) provided by IMS Health, does not distinguish between medicines used for prevention and treatment. Neither does it provide a breakdown at sub-national level for local commissioning organisations. The available data records usage in terms on volume dispensed.
The following table provides information on high cholesterol medicines, as defined by British National Formulary (BNF) Section 2.12 Lipid-regulating drugs, for hospitals in England, covering the 10 year period 2004-05 to 2013-14.
Volume of cholesterol medicines dispensed in hospitals in England, as defined by BNF Section 2.12 | |
Year | Volume of packs (000’s) |
2004-05 | 1,077.3 |
2005-06 | 1,170.9 |
2006-07 | 1,198.8 |
2007-08 | 1,214.0 |
2008-09 | 1,299.8 |
2009-10 | 1,326.6 |
2010-11 | 1,266.2 |
2011-12 | 1,196.1 |
2012-13 | 1,199.1 |
2013-14 | 1,202.7 |
Source: HPAI
Note that the volume of packs figures for hospitals are not comparable with the number of prescription items dispensed in the community.
Asked by: Simon Burns (Conservative - Chelmsford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, pursuant to the Answer of 11 November 2014 to Question 213785, what the terms of reference are for the Pneumococcal sub-committee's review; if he will place in the Library a copy of the terms of reference of that review; and if he will make a statement.
Answered by Jane Ellison
The terms of reference for the pneumococcal subcommittee of the Joint Committee on Vaccination and Immunisation (JCVI) will be agreed at its first meeting, to be held in spring 2015.
Once agreed, the terms of reference will be published in the minutes of the sub-committee meeting and available for public access on the gov.uk website.
Asked by: Simon Burns (Conservative - Chelmsford)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health, with reference to paragraph 54 of the minutes of the meeting of 4 June 2014 of the Joint Committee on Vaccination and Immunisation, over what period of time Public Health England intends to revise the cost effectiveness model of pneumococcal polysaccharide vaccine to include the latest epidemiological data on pneumococcal disease in the UK; and if he will make a statement.
Answered by Jane Ellison
Public Health England (PHE) will review modelling undertaken on the impact and cost-effectiveness of the Pneumococcal Polysaccharide Vaccine (PPV) programme in over-65 year olds using the latest epidemiological data on invasive pneumococcal disease in the United Kingdom. PHE will report its findings to the Pneumococcal Sub-committee of the Joint Committee on Vaccination and Immunisation (JCVI). It is anticipated that the Pneumococcal Sub-committee will meet for the first time in spring 2015.
At this meeting of the Pneumococcal Sub-committee members will review information including epidemiological data and PHE’s report on PPV impact and cost-effectiveness. Should all the required data be available to the Sub-committee, and subject to the requirement for additional meetings and, if required, additional modelling, it is anticipated that it will report to the JCVI main committee. The JCVI will form advice at the October 2015 meeting. The minutes of this meeting will be published in winter 2015.